Flywheel Secures $27.5M, Propelling Medical Imaging AI and Clinical Trials
January 11, 2026, 9:36 am
Location: United States
Employees: 51-200
Founded date: 2015
Total raised: $121.83M
Flywheel, a key player in medical imaging data management, has closed $27.5 million in equity funding. This significant investment fuels product innovation. It accelerates growth, especially in clinical trials and AI model development. The Minneapolis-based firm reported record 2025 momentum. It expanded offerings to enterprise imaging management. This includes new compliance tools for biopharma and medical device workflows. Serving top global pharmaceutical companies and academic centers, Flywheel leverages this capital. It enhances imaging data aggregation, curation, and analysis. The company drives efficiencies. It improves data quality for critical healthcare research. This round reinforces Flywheel’s leadership. It propels vital advancements in digital health and AI.
Flywheel recently secured substantial capital. The company closed a $27.5 million equity funding round. This financing signals robust investor confidence. Novalis Lifesciences and 8VC led the investment. They spearheaded an oversubscribed $25 million portion of the total. This funding infusion underscores Flywheel’s strategic value. It solidifies its crucial role in health technology. The capital positions Flywheel for aggressive expansion.
The new funds will propel key initiatives. Flywheel targets accelerated product innovation. This includes developing advanced platform features. Growth strategies also receive significant backing. A primary focus lies in image management for clinical trials. Enhancing capabilities for AI model development is another critical objective. These investments aim to expand Flywheel’s technological edge. They ensure the platform remains at the forefront of medical imaging solutions.
Flywheel's medical imaging platform has seen significant evolution. It has broadened its scope. The company now offers enterprise imaging management. This moves beyond its initial core lab research focus. The expanded platform addresses the diverse and complex data needs. It serves the entire healthcare ecosystem. Its capabilities span large-scale imaging data aggregation. Advanced curation tools simplify complex datasets. Robust analysis features empower deep insights. This comprehensive approach differentiates Flywheel in the competitive health tech market.
New products and tools enhance the platform's utility. Flywheel launched advanced video viewing and annotation capabilities. These tools streamline diverse research workflows. A major development is Flywheel Validated. This offering specifically addresses regulatory compliance. It streamlines 21 CFR Part 11-compliant workflows for clinical trials. This ensures data integrity. It enables earlier access to crucial imaging data. Provenance is meticulously maintained. The solution reduces operational costs. It significantly improves overall data quality. This meets rigorous industry standards.
Medical imaging data represents a cornerstone of modern medicine. It fuels discovery. It drives diagnostics. However, managing this vast, sensitive data presents challenges. Data silos often impede progress. Complex research workflows demand automation. Preparing imaging data for advanced AI development requires specialized tools. Flywheel provides an integrated solution. It breaks down these barriers. Its platform streamlines the entire data lifecycle. This empowers researchers and clinicians. They can unlock the full potential of their imaging assets for critical health advancements.
Flywheel's market presence is impressive. Its platform is utilized by leading institutions worldwide. Ten of the top 20 global pharmaceutical companies leverage Flywheel solutions. Similarly, ten of the top 20 academic medical centers depend on its technology. Its customer base spans major biopharmaceutical firms. Medical device manufacturers form another key segment. Prominent academic research institutions globally trust Flywheel for their complex data needs. This widespread adoption underscores its efficacy and reliability in diverse healthcare settings.
The company's 2025 performance reported record momentum. New business growth reached 43% year-over-year. Committed revenue increased by a significant 40%. Annual recurring revenue (ARR) from pharmaceutical and medical device customers showed exceptional growth. This segment's ARR surged by 106% compared to the prior year. Overall net revenue retention exceeded an impressive 110%. These robust financial metrics highlight Flywheel's strong market traction. They reflect its increasing value to customers within the rapidly expanding digital health sector.
Flywheel has strategically expanded its capabilities. It now better serves medical device companies. Research sponsors gain enhanced support. Partner sites benefit from improved integration. This broadens Flywheel's impact across the healthcare continuum. It facilitates faster movement from initial scientific discovery to critical clinical decisions. Imaging data is increasingly viewed as a strategic asset. Flywheel enables its maximal utilization. This accelerates the pace of medical innovation.
The future of healthcare heavily relies on imaging data. Its value is only beginning to be fully realized. Artificial intelligence is transforming diagnostics. It revolutionizes drug discovery processes. Effective data management forms the foundation for these breakthroughs. Compliant workflows ensure data integrity and trust. Access to a connected healthcare ecosystem is paramount for collaborative research. Flywheel positions itself at this critical intersection. It empowers organizations to maximize value from their imaging assets.
This substantial funding solidifies Flywheel’s market leadership. It reinforces the company's commitment to continuous innovation. Flywheel empowers researchers and clinicians with vital tools. They gain unprecedented agility. They unlock deeper insights into patient data. The company continues to drive forward. Its impact on medical research deepens. Flywheel plays a pivotal role in shaping the future of digital health and AI in medicine.
Flywheel recently secured substantial capital. The company closed a $27.5 million equity funding round. This financing signals robust investor confidence. Novalis Lifesciences and 8VC led the investment. They spearheaded an oversubscribed $25 million portion of the total. This funding infusion underscores Flywheel’s strategic value. It solidifies its crucial role in health technology. The capital positions Flywheel for aggressive expansion.
The new funds will propel key initiatives. Flywheel targets accelerated product innovation. This includes developing advanced platform features. Growth strategies also receive significant backing. A primary focus lies in image management for clinical trials. Enhancing capabilities for AI model development is another critical objective. These investments aim to expand Flywheel’s technological edge. They ensure the platform remains at the forefront of medical imaging solutions.
Flywheel's medical imaging platform has seen significant evolution. It has broadened its scope. The company now offers enterprise imaging management. This moves beyond its initial core lab research focus. The expanded platform addresses the diverse and complex data needs. It serves the entire healthcare ecosystem. Its capabilities span large-scale imaging data aggregation. Advanced curation tools simplify complex datasets. Robust analysis features empower deep insights. This comprehensive approach differentiates Flywheel in the competitive health tech market.
New products and tools enhance the platform's utility. Flywheel launched advanced video viewing and annotation capabilities. These tools streamline diverse research workflows. A major development is Flywheel Validated. This offering specifically addresses regulatory compliance. It streamlines 21 CFR Part 11-compliant workflows for clinical trials. This ensures data integrity. It enables earlier access to crucial imaging data. Provenance is meticulously maintained. The solution reduces operational costs. It significantly improves overall data quality. This meets rigorous industry standards.
Medical imaging data represents a cornerstone of modern medicine. It fuels discovery. It drives diagnostics. However, managing this vast, sensitive data presents challenges. Data silos often impede progress. Complex research workflows demand automation. Preparing imaging data for advanced AI development requires specialized tools. Flywheel provides an integrated solution. It breaks down these barriers. Its platform streamlines the entire data lifecycle. This empowers researchers and clinicians. They can unlock the full potential of their imaging assets for critical health advancements.
Flywheel's market presence is impressive. Its platform is utilized by leading institutions worldwide. Ten of the top 20 global pharmaceutical companies leverage Flywheel solutions. Similarly, ten of the top 20 academic medical centers depend on its technology. Its customer base spans major biopharmaceutical firms. Medical device manufacturers form another key segment. Prominent academic research institutions globally trust Flywheel for their complex data needs. This widespread adoption underscores its efficacy and reliability in diverse healthcare settings.
The company's 2025 performance reported record momentum. New business growth reached 43% year-over-year. Committed revenue increased by a significant 40%. Annual recurring revenue (ARR) from pharmaceutical and medical device customers showed exceptional growth. This segment's ARR surged by 106% compared to the prior year. Overall net revenue retention exceeded an impressive 110%. These robust financial metrics highlight Flywheel's strong market traction. They reflect its increasing value to customers within the rapidly expanding digital health sector.
Flywheel has strategically expanded its capabilities. It now better serves medical device companies. Research sponsors gain enhanced support. Partner sites benefit from improved integration. This broadens Flywheel's impact across the healthcare continuum. It facilitates faster movement from initial scientific discovery to critical clinical decisions. Imaging data is increasingly viewed as a strategic asset. Flywheel enables its maximal utilization. This accelerates the pace of medical innovation.
The future of healthcare heavily relies on imaging data. Its value is only beginning to be fully realized. Artificial intelligence is transforming diagnostics. It revolutionizes drug discovery processes. Effective data management forms the foundation for these breakthroughs. Compliant workflows ensure data integrity and trust. Access to a connected healthcare ecosystem is paramount for collaborative research. Flywheel positions itself at this critical intersection. It empowers organizations to maximize value from their imaging assets.
This substantial funding solidifies Flywheel’s market leadership. It reinforces the company's commitment to continuous innovation. Flywheel empowers researchers and clinicians with vital tools. They gain unprecedented agility. They unlock deeper insights into patient data. The company continues to drive forward. Its impact on medical research deepens. Flywheel plays a pivotal role in shaping the future of digital health and AI in medicine.